SCHEMBL1787833

SCHEMBL1787833

CCN1CCc2ccc(C(=O)NCc3cccnc3)cc2CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
USP2 O75604 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HTT P42858 2/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
TSHR P16473 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
BLM P54132 1/20 0.53
GAA P10253 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
CYP2C19 P33261 1/20 0.53
PIK3CA P42336 1/20 0.52
KMT2A Q03164 1/20 0.52
NAMPT P43490 1/20 0.52
ROCK2 O75116 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1788721 0.87 GAA (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL1790748 0.87 KDM4E (0.54) LMNASMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL1788918 0.82 LMNA (0.56) LMNASMN1; SMN2ALDH1A1L3MBTL1USP2
SCHEMBL1791073 0.82 LMNA (0.56) LMNASMN1; SMN2ALDH1A1L3MBTL1USP2
SCHEMBL1791072 0.82 LMNA (0.56) LMNASMN1; SMN2ALDH1A1L3MBTL1USP2
SCHEMBL1787602 0.82 ROCK2 (0.52) LMNASMN1; SMN2KMT2AROCK2
SCHEMBL12608451 0.81 TP53 (0.55) LMNASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL1788003 0.80 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1MAPTCYP1A2CYP2C19
SCHEMBL1791213 0.80 MMP13 (0.62) LMNAALDH1A1MAPTCYP3A4GAA
SCHEMBL1788936 0.80 KDM4E (0.57) LMNAALDH1A1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 LMNA 2172/4885SMN1; SMN2 4393/4885ALDH1A1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.